Zimberelimab and quemliclustat with chemotherapy for pancreatic cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies how well zimberelimab and quemliclustat work together with standard chemotherapy for people with borderline resectable or locally advanced pancreatic cancer. It may help shrink the tumor and make treatment more effective before or around the time surgery is considered for some patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older and able to sign informed consent.
- You have pancreatic adenocarcinoma that has not been treated before, and it is either borderline resectable or locally advanced (not spreading to distant organs).
- Your body is strong enough for treatment (ECOG performance status 0–1).
- Your recent blood and organ tests are within allowed ranges (including white blood cell, platelets, hemoglobin, kidney function, and liver enzymes).
- You have recovered from any major surgery and are not currently needing high-dose steroids (or they must be stopped before starting).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the drug IBI343 to chemotherapy before surgery can help people with borderline resectable pancreatic cancer. It is for those whose tumors have a specific protein called CLDN18.2 and have not spread to other parts of the body.
This trial studies whether giving chemotherapy before surgery, and possibly adding a focused high-dose radiation treatment, can improve outcomes for people with borderline resectable pancreatic cancer. It aims to shrink or control the cancer and help more patients get to surgery safely.
This trial tests a combination of drugs for people with localized pancreatic cancer who have already completed 8 cycles of modified FOLFIRINOX chemotherapy before surgery. The goal is to see if adding these drugs after chemo and radiation helps improve outcomes.
This trial tests a new combination of radiation, chemotherapy, an immunotherapy drug (PD-1 inhibitor), and a medicine that boosts the immune system (thymalfasin) for people with pancreatic cancer that is just on the edge of being removable by surgery. The goal is to see if this treatment can shrink the tumor enough to make surgery possible.
This trial tests a combination of a cancer immunotherapy (zimberelimab) and three chemotherapy drugs (SIRIOX) as a second-line treatment for people whose pancreatic cancer has stopped responding to the AG regimen. The goal is to see if this new mix can shrink tumors or slow progression.
This trial tests a combination of chemotherapy drugs (AG and FOLFIRINOX) with an immunotherapy drug (PD-L1 antibody) to shrink pancreatic tumors that are borderline resectable or locally advanced, making them removable by surgery. It's for people who haven't had any previous cancer treatment.
Hear when a new Borderline Resectable Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.